Role of inflammation and its mediators in acute ischemic stroke

Journal of Cardiovascular Translational Research

Volumn 6, Issue 5, 2013, Pages 834-851

  Jin, Rong ^a   Liu, Lin ^a   Zhang, Shihao ^a   Nanda, Anil ^a   Li, Guohong ^a  

^a LOUISIANA STATE UNIVERSITY HEALTH SCIENCES CENTER   (United States)

Author keywords

Brain ischemia; Inflammation; Inflammatory mediators; Leukocytes

Indexed keywords

ARUNDIC ACID; CD11B ANTIGEN; CD31 ANTIGEN; ENLIMOMAB; FRACTALKINE; GELATINASE B; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERCELLULAR ADHESION MOLECULE 1; INTERCELLULAR ADHESION MOLECULE 1 ANTIBODY; INTERLEUKIN 10; INTERLEUKIN 1ALPHA; INTERLEUKIN 1BETA; INTERLEUKIN 6; L SELECTIN; MINOCYCLINE; MITOGEN ACTIVATED PROTEIN KINASE; MUCOSAL ADDRESSIN CELL ADHESION MOLECULE 1; NEUROPROTECTIVE AGENT; PADGEM PROTEIN; RECOMBINANT INTERLEUKIN 6; SELECTIN; SOMATOMEDIN C; STRESS ACTIVATED PROTEIN KINASE INHIBITOR; TOLL LIKE RECEPTOR 2; TOLL LIKE RECEPTOR 4; TRANSFORMING GROWTH FACTOR BETA; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG; UNINDEXED DRUG; VASCULAR CELL ADHESION MOLECULE 1; VASCULAR CELL ADHESION MOLECULE 1 ANTIBODY;

ANTIINFLAMMATORY ACTIVITY; ARTICLE; ASTROCYTE; ATHEROSCLEROSIS; BRAIN CELL; BRAIN ISCHEMIA; CELL DAMAGE; CELL DEATH; CELL INFILTRATION; CELL PROLIFERATION; CEREBROVASCULAR ACCIDENT; CYTOKINE PRODUCTION; DRUG EFFICACY; DRUG RESPONSE; HUMAN; IMMUNOCOMPETENT CELL; INFLAMMATION; INFLAMMATORY CELL; LEUKOCYTE; MICROGLIA; NEUROPROTECTION; NEUTROPHIL CHEMOTAXIS; NONHUMAN; PATHOGENESIS; PHARMACOLOGICAL BLOCKING; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN PHOSPHORYLATION; PROTEIN SECRETION; PROTEIN TARGETING; T LYMPHOCYTE; UPREGULATION;

ANIMALS; BRAIN ISCHEMIA; HUMANS; INFLAMMATION; INFLAMMATION MEDIATORS; PROGNOSIS; RISK FACTORS; SIGNAL TRANSDUCTION; STROKE;

EID: 84885638937     PISSN: 19375387     EISSN: 19375395     Source Type: Journal    
DOI: 10.1007/s12265-013-9508-6     Document Type: Article

References (197)

1. Wang, X. (2005). Investigational anti-inflammatory agents for the treatment of ischemic brain injury. Expert Opinion on Investigational Drugs, 14, 393-409.
2. Barone, F. C., & Feuerstein, G. Z. (1999). Inflammatory mediators and stroke: new opportunities for novel therapeutics. Journal of Cerebral Blood Flow and Metabolism, 19, 819-834.
3. Chamorro, A., & Hallenbeck, J. (2006). The harms and benefits of inflammatory and immune responses in vascular disease. Stroke, 37, 291-293.
4. Samson, Y., Lapergue, B., & Hosseini, H. (2005). Inflammation and ischaemic stroke: current status and future perspectives. Reviews Neurology (Paris), 161, 1177-1182.
5. Yilmaz, G., & Granger, D. N. (2008). Cell adhesion molecules and ischemic stroke. Neurological Research, 30, 783-793.
6. Emsley, H. C., & Hopkins, S. J. (2008). Acute ischaemic stroke and infection: recent and emerging concepts. Lancet Neurology, 7, 341-353.
7. McColl, B. W., Allan, S. M., & Rothwell, N. J. (2009). Systemic infection, inflammation and acute ischemic stroke. Neuroscience, 158, 1049-1061.
8. Jin, R., Yang, G., & Li, G. (2010). Inflammatory mechanisms in ischemic stroke: role of inflammatory cells. Journal of Leukocyte Biology, 87, 779-89.
9. Iadecola, C., & Anrather, J. (2011). The immunology of stroke: from mechanisms to translation. Nature Medicine, 17, 796-808.
10. Hallenbeck, J. M. (1996). Significance of the inflammatory response in brain ischemia. Acta Neurochirurgica. Supplement, 66, 27-31.
11. Chopp, M., Li, Y., Jiang, N., Zhang, R. L., & Prostak, J. (1996). Antibodies against adhesion molecules reduce apoptosis after transient middle cerebral artery occlusion in rat brain. Journal of Cerebral Blood Flow and Metabolism, 16, 578-584.
12. Connolly, E. S., Jr., Winfree, C. J., Prestigiacomo, C. J., Kim, S. C., Choudhri, T. F., Hoh, B. L., et al. (1997). Exacerbation of cerebral injury in mice that express the P-selectin gene: identification of P-selectin blockade as a new target for the treatment of stroke. Circulation Research, 81, 304-310.
13. Garau, A., Bertini, R., Colotta, F., Casilli, F., Bigini, P., Cagnotto, A., et al. (2005). Neuroprotection with the CXCL8 inhibitor repertaxin in transient brain ischemia. Cytokine, 30, 125-131.
14. Yenari, M. A., Kunis, D., Sun, G. H., Onley, D., Watson, L., Turner, S., et al. (1998). Hu23F2G, an antibody recognizing the leukocyte CD11/CD18 integrin, reduces injury in a rabbit model of transient focal cerebral ischemia. Experimental Neurology, 153, 223-233.
15. Zheng, Z., & Yenari, M. A. (2004). Post-ischemic inflammation: molecular mechanisms and therapeutic implications. Neurological Research, 26, 884-892.
16. Barone, F. C., Arvin, B., White, R. F., Miller, A., Webb, C. L., Lysko, P. G., et al. (1997). Tumor necrosis factor-α: a mediator of focal ischemic brain injury. Stroke, 28, 1233-1244.
17. Rothwell, N., Allan, S., & Toulmond, S. (1997). The role of interleukin 1 in acute neurodegeneration and stroke: pathophysiological and therapeutic implications. Journal of Clinical Investigation, 100, 2648-2652.
18. Felger, J. C., Abe, T., Kaunzner, U. W., Gottfried-Blackmore, A., Gal-Toth, J., McEwen, B. S., et al. (2010). Brain dendritic cells in ischemic stroke: time course, activation state, and origin. Brain, Behavior, and Immunity, 24, 724-737.
19. Tanaka, R., Komine-Kobayashi, M., Mochizuki, H., Yamada, M., Furuya, T., Migita, M., et al. (2003). Migration of enhanced green fluorescent protein expressing bone marrow-derived microglia/macrophage into the mouse brain following permanent focal ischemia. Neuroscience, 117, 531-539.
20. Konsman, J. P., Drukarch, B., & Van Dam, A. M. (2007). (Peri)vascular production and action of pro-inflammatory cytokines in brain pathology. Clinical Science (London, England), 112, 1-25.
21. Shigematsu, T., Wolf, R. E., & Granger, D. N. (2002). T-lymphocytes modulate the microvascular and inflammatory responses to intestinal ischemia-reperfusion. Microcirculation, 9, 99-109.
22. Zwacka, R. M., Zhang, Y., Halldorson, J., Schlossberg, H., Dudus, L., & Engelhardt, J. F. (1997). CD4(+) T-lymphocytes mediate ischemia/reperfusion-induced inflammatory responses in mouse liver. Journal of Clinical Investigation, 100, 279-289.
23. Yilmaz, G., Arumugam, T. V., Stokes, K. Y., & Granger, D. N. (2006). Role of T lymphocytes and interferon-γ in ischemic stroke. Circulation, 113, 2105-2112.
24. Kreutzberg, G. W. (1996). Microglia: a sensor for pathological events in the CNS. Trends in Neurosciences, 19, 312-318.
25. Thomas, W. E. (1992). Brain macrophages: evaluation of microglia and their functions. Brain Research, 17, 61-74.
26. Lalancette-Hébert, M., Gowing, G., Simard, A., Weng, Y. C., & Kriz, J. (2007). Selective ablation of proliferating microglial cells exacerbates ischemic injury in the brain. Journal of Neuroscience, 27, 2596-2605.
27. Lai, A. Y., & Todd, K. G. (2006). Microglia in cerebral ischemia: molecular actions and interactions. Canadian Journal of Physiology and Pharmacology, 84, 49-59.
28. Denes, A., Vidyasagar, R., Feng, J., Narvainen, J., McColl, B. W., Kauppi-nen, R. A., et al. (2007). Proliferating resident microglia after focal cerebral ischaemia in mice. Journal of Cerebral Blood Flow and Metabolism, 27, 1941-1953.
29. George, B., Robin, E., White, Y. O., Lijun, X., & Giffard, G. R. (2011). Astrocytes: targets for neuroprotection in stroke. Central Nervous System Agents in Medicinal Chemistry, 11, 164-173.
30. Nowicka, D., Rogozinska, K., Aleksy, M., Witte, O. W., & Skangiel-Kramska, J. (2008). Spatiotemporal dynamics of astroglial and microglial responses after photothrombotic stroke in the rat brain. Acta Neurobiologiae Experimentalis (Wars), 68, 155-168.
31. Zhu, Y., Roth-Eichhorn, S., Braun, N., Culmsee, C., Rami, A., & Krieglstein, J. (2000). The expression of transforming growth factor-beta1 (TGF-beta1) in hippocampal neurons: a temporary upregulated protein level after transient forebrain ischemia in the rat. Brain Research, 866, 286-298.
32. Benveniste, E. N. (1998). Cytokine actions in the central nervous system. Cytokine & Growth Factor Reviews, 9, 259-275.
33. Che, X., Ye, W., Panga, L., Wu, D. C., & Yang, G. Y. (2001). Monocyte chemoattractant protein-1 expressed in neurons and astrocytes during focal ischemia in mice. Brain Research, 902, 171-177.
34. Dong, Y., & Benveniste, E. N. (2001). Immune function of astrocytes. Glia, 36, 180-190.
35. Wang, W., Redecker, C., Yu, Z. Y., Xie, M. J., Tian, D. S., Zhang, L., et al. (2008). Rat focal cerebral ischemia induced astrocyte proliferation and delayed neuronal death are attenuated by cyclin-dependent kinase inhibition. Journal of Clinical Neuroscience, 15, 278-285.
36. Sharif, A., Legendre, P., Prevot, V., Allet, C., Romao, L., Studler, J. M., et al. (2007). Transforming growth factor alpha promotes sequential conversion of mature astrocytes into neural progenitors and stem cells. Oncogene, 26, 2695-2706.
37. Justicia, C., Perez-Asensio, F. J., Burguete, M. C., Salom, J. B., & Planas, A. M. (2001). Administration of transforming growth factor-alpha reduces infarct volume after transient focal cerebral ischemia in the rat. Journal of Cerebral Blood Flow and Metabolism, 21, 1097-1104.
38. Meistrell, M. E., 3rd, Botchkina, G. I., Wang, H., Di Santo, E., Cockroft, K. M., Bloom, O., et al. (1997). Tumor necrosis factor is a brain damaging cytokine in cerebral ischemia. Shock, 8, 341-348.
39. 2+ accumulation. Proceedings of the National Academy of Sciences of the United States of America, 92, 9328-9332.
40. Lambertsen, K. L., Clausen, B. H., Babcock, A. A., Gregersen, R., Fenger, C., Nielsen, H. H., et al. (2009). Microglia protect neurons against ischemia by synthesis of tumor necrosis factor. Journal of Neuroscience, 29, 1319-1330.
41. Boutin, H., LeFeuvre, R. A., Horai, R., Asano, M., Iwakura, Y., & Rothwell, N. J. (2001). Role of IL-1alpha and IL-1beta in ischemic brain damage. Journal of Neuroscience, 21, 5528-5534.
42. Yamasaki, Y., Matsuura, N., Shozuhara, H., Onodera, H., Itoyama, Y., & Kogure, K. (1995). Interleukin-1 as a pathogenetic mediator of ischemic brain damage in rats. Stroke, 26, 676-680.
43. Loddick, S. A., Turnbull, A. V., & Rothwell, N. J. (1998). Cerebral interleukin-6 is neuroprotective during permanent focal cerebral ischemia in the rat. Journal of Cerebral Blood Flow and Metabolism, 18, 176-179.
44. Stamatovic, S. M., Shakui, P., Keep, R. F., Moore, B. B., Kunkel, S. L., Van, R. N., et al. (2005). Monocyte chemoattractant protein-1 regulation of blood-brain barrier permeability. Journal of Cerebral Blood Flow and Metabolism, 25, 593-606.
45. Soriano, S. G., Amaravadi, L. S., Wang, Y. F., Zhou, H., Yu, G. X., Tonra, J. R., et al. (2002). Mice deficient in fractalkine are less susceptible to cerebral ischemia-reperfusion injury. Journal of Neuroimmunology, 125, 59-65.
46. Spera, P. A., Ellison, J. A., Feuerstein, G. Z., & Barone, F. C. (1998). IL-10 reduces rat brain injury following focal stroke. Neuroscience Letters, 251, 189-192.
47. Ooboshi, H., Ibayashi, S., Shichita, T., Kumai, Y., Takada, J., & Ago, T. (2005). Postischemic gene transfer of interleukin-10 protects against both focal and global brain ischemia. Circulation, 111, 913-919.
48. Pang, L., Ye, W., Che, X. M., Roessler, B. J., Betz, A. L., & Yang, G. Y. (2001). Reduction of inflammatory response in the mouse brain with adenoviral-mediated transforming growth factor-ss1 expression. Stroke, 32, 544-552.
49. Ruocco, A., Nicole, O., Docagne, F., Ali, C., Chazalviel, L., Komesli, S., et al. (1999). A transforming growth factor-b antagonist unmasks the neuroprotective role of this endogenous cytokine in excitotoxic and ischemic brain injury. Journal of Cerebral Blood Flow and Metabolism, 19, 1345-1353.
50. Zhang, Y., Wei, X., Liu, L., Liu, S., Wang, Z., Zhang, B., et al. (2012). TIPE2, a novel regulator of immunity, protects against experimental stroke. Journal of Biological Chemistry, 287, 32546-32555.
51. Kooijman, R., Sarre, S., Michotte, Y., & Keyser, D. J. (2009). Insulin-like growth factor I: a potential neuroprotective compound for the treatment of acute ischemic stroke? Stroke, 404, e83-88.
52. Denti, L., Annoni, V., Cattadori, E., Salvagnini, M. A., Visioli, S., & Merli, M. F. (2004). Insulin-like growth factor 1 as a predictor of ischemic stroke outcome in the elderly. American Journal of Medicine, 117, 312-317.
53. Liu, T., Clark, R. K., McDonnell, P. C., Young, P. R., White, R. F., & Barone, F. C. (1994). Tumor necrosis factor-α expression in ischemic neurons. Stroke, 25, 1481-1488.
54. Wang, X., Yue, T. L., Barone, F. C., White, R. F., Gagnon, R. C., & Feuerstein, G. Z. (1994). Concomitant cortical expression of TNF-α and IL-1 α mRNAs follows early response gene expression in transient focal ischemia. Molecular and Chemical Neuropathology, 23, 103-114.
55. Murakami, Y., Saito, K., Hara, A., Zhu, Y., Sudo, K., Niwa, M., et al. (2005). Increases in tumor necrosis factor-alpha following transient global cerebral ischemia do not contribute to neuron death in mouse hippocampus. Journal of Neurochemistry, 93, 1616-1622.
56. Offner, H., Subramanian, S., Parker, S. M., Afentoulis, M. E., Vandenbark, A. A., & Hurn, P. D. (2006). Experimental stroke induces massive, rapid activation of the peripheral immune system. Journal of Cerebral Blood Flow and Metabolism, 26, 654-665.
57. Hallenbeck, J. M. (2002). The many faces of tumor necrosis factor in stroke. Nature Medicine, 8, 1363-1368.
58. Ginis, I., Jaiswal, R., Klimanis, D., Liu, J., Greenspon, J., & Hallenbeck, J. M. (2002). TNF-alpha-induced tolerance to ischemic injury involves differential control of NF-kappaB transactivation: the role of NF-kappaB association with p300 adaptor. Journal of Cerebral Blood Flow and Metabolism, 22, 142-152.
59. Alikhani, M., Alikhani, Z., Raptis, M., & Graves, D. T. J. (2004). TNF-alpha in vivo stimulates apoptosis in fibroblasts through caspase-8 activation and modulates the expression of pro-apoptotic genes. Cell Physiology, 201, 341-348.
60. Plumpe, J., Malek, N. K., Bock, C. T., Rakemann, T., Manns, M. P., & Trautwein, C. (2000). NF-kappaB determines between apoptosis and proliferation in hepatocytes during liver regeneration. American Journal of Physiology - Gastrointestinal and Liver Physiology, 278, 173-183.
61. Zeng, L., Liu, J., Wang, Y., Wang, L., Weng, S., Chen, S., et al. (2012). Cocktail blood biomarkers: prediction of clinical outcomes in patients with acute ischemic stroke. European Neurology, 69(2), 68-75.
62. Thornberry, N. A., Bull, H. G., Calaycay, J. R., Chapman, K. T., Howard, A. D., & Kostura, M. J. (1992). A novel heterodimeric cysteine protease is required for interleukin-1 beta processing in monocytes. Nature, 356, 768-774.
63. Dinarello, C. A. (1996). Biologic basis for interleukin-1 in disease. Blood, 15, 2095-2147.
64. Black, R. A., Kronheim, S. R., & Sleath, P. R. (1989). Activation of interleukin-1β by a co-induced protease. FEBS Letters, 247, 386-390.
65. Schonbeck, V., Mach, F., & Libby, P. (1998). Generation of biologically active IL-1β by matrix metalloproteinase a novel caspase-1 independent pathway of IL-1β processing. Journal of Immunology, 161, 3340-3346.
66. Dinarello, C. A., & Wolff, S. M. (1993). The role of interleukin-1 in disease. New England Journal of Medicine, 328, 106-113.
67. Bankers-Fulbright, J. L., Kalli, K. R., & McLean, D. J. (1996). IL-1 signal transduction. Life Sciences, 59, 61-83.
68. Rothwell, N. J., & Luheshi, G. N. (2000). Interleukin 1 in the brain: biology, pathology and therapeutic target. Trends in Neurosciences, 23, 618-625.
69. Koga, S., Ogawa, S., Kuwabara, K., Brett, J., Leavy, J. A., & Ryan, J. (1992). Synthesis and release of interleukin 1 by reoxygenated human mononuclear phagocytes. Journal of Clinical Investigation, 90, 1007-1015.
70. Basu, A., Lazovic, J., Krady, J. K., Mauger, D. T., Rothstein, R. P., Smith, M. B., et al. (2005). Interleukin-1 and the interleukin-1 type 1 receptor are essential for the progressive neurodegeneration that ensues subsequent to a mild hypoxic/ischemic injury. Journal of Cerebral Blood Flow and Metabolism, 25, 17-29.
71. Herrmann, O., Tarabin, V., Suzuki, S., Attigah, N., Coserea, I., & Schneider, A. (2003). Regulation of body temperature and neuroprotection by endogenous interleukin-6 in cerebral ischemia. Journal of Cerebral Blood Flow and Metabolism, 23, 406-415.
72. Waje-Andreassen, U., Kråkenes, J., Ulvestad, E., Thomassen, L., Myhr, K. M., Aarseth, J., et al. (2005). IL-6: an early marker for outcome in acute ischemic stroke. Acta Neurologica Scandinavica, 111, 360-365.
73. Scheller, J., Chalaris, A., Schmidt-Arras, D., & Rose-John, S. (1813). The pro- and anti-inflammatory properties of the cytokine interleukin-6. Biochimica et Biophysica Acta, 2011, 878-888.
74. Connolly, E. S. J., Winfree, C. J., Springer, T. A., Naka, Y., Liao, H., & Yan, S. D. (1996). Cerebral protection in homozygous null ICAM-1 mice after middle cerebral artery occlusion. Role of neutrophil adhesion in the pathogenesis of stroke. Journal of Clinical Investigation, 97, 209-16.
75. Moore, K. L., Eaton, S. F., Lyons, D. E., Lichenstein, H. S., Cummings, R. D., & McEver, R. P. (1994). The P-selectin glycoprotein ligand from human neutrophils displays sialylated, fucosylated, O-linked poly-N- acetyllactosamine. Journal of Biological Chemistry, 269, 23318-23327.
76. Stenberg, P. E., Shuman, M. A., Levine, S. P., & Bainton, D. F. (1984). Redistribution of alpha-granules and their contents in thrombin-stimulated platelets. Journal of Cell Biology, 98, 748-760.
77. Bargatze, R. F., Kurk, S., Butcher, E. C., & Jutila, M. A. (1994). Neutrophils roll on adherent neutrophils bound to cytokine-induced endothelial cells via L-selectin on the rolling cells. Journal of Experimental Medicine, 180, 1785-1792.
78. Mayadas, T. N., Johnson, R. C., Rayburn, H., Hynes, R. O., & Wagner, D. D. (1993). Leukocyte rolling and extravasation are severely compromised in P-selectin deficient mice. Cell, 74, 541-554.
79. Huang, J., Kim, L. J., Mealey, R., Marsh, H. C., Zhang, Y., Tenner, A. J., et al. (1999). Neuronal protection in stroke by an sLex-glycosylated complement inhibitory protein. Science, 285, 595-599.
80. Huang, J., Choudhri, T. F., Winfree, C. J., McTaggart, R. A., Kiss, S., Mocco, J., et al. (2000). Postischemic cerebrovascular E-selectin expression mediates tissue injury in murine stroke. Stroke, 31, 3047-3053.
81. Mocco, J., Choudhri, T., Huang, J., Harfeldt, E., Efros, L., Klingbeil, C., et al. (2002). HuEP5C7 as a humanized monoclonal anti-E/P-selectin neurovascular protective strategy in a blinded placebo-controlled trial of nonhuman primate stroke. Circulation Research, 91, 907-914.
82. Lehmberg, J., Beck, J., Baethmann, A., & Uhl, E. (2006). Effect of P-selectin inhibition on leukocyte endothelium interaction and survival after global cerebral ischemia. Journal of Neurology, 253, 357-363.
83. Cha, J. K., Jeong, M. H., Kim, E. K., Lim, Y. J., Ha, B. R., & Kim, S. H. (2002). Surface expression of P-selectin on platelets is related with clinical worsening in acute ischemic stroke. Journal of Korean Medical Science, 17, 811-816.
84. Zhao, D. X., Feng, J., Cong, S. Y., & Zhang, W. (2012). Association of E-selectin gene polymorphisms with ischemic stroke in a Chinese Han population. Journal of Neuroscience Research, 90, 1782-1787.
85. + exchanger enhances low pH-induced L-selectin shedding and beta2-integrin surface expression in human neutrophils. American Journal of Physiology. Cell Physiology, 295, C1454-1463.
86. Springer, T. A. (1990). Adhesion receptors of the immune system. Nature, 346, 425.
87. Gahmberg, C. G. M., Tolvanen, P., & Kotovuori. (1997). Leukocyte adhesion: structure and function of human leukocyte β2-integrins and their cellular ligands. European Journal of Biochemistry, 245, 215-232.
88. Diacovo, T. G., de Fougerolles, A. R., Bainton, D. F., & Springer, T. A. (1994). A functional integrin ligand on the surface of platelets: intercellular adhesion molecule-2. Journal of Clinical Investigation, 94, 1243-1251.
89. Zhang, R. L., Chopp, M., Chen, H., & Garcia, J. H. (1994). Temporal profile of ischemic tissue damage, neutrophil response, and vascular plugging following permanent and transient (2H) middle cerebral artery occlusion in the rat. Journal of Neurological Sciences, 125, 3-10.
90. Kanemoto, Y., Nakase, H., Akita, N., & Sakaki, T. (2002). Effects of anti-intercellular adhesion molecule-1 antibody on reperfusion injury induced by late reperfusion in the rat middle cerebral artery occlusion model. Neurosurgery, 51, 1034-1041.
91. Kitagawa, K., Matsumoto, M., Mabuchi, T., Yagita, Y., Ohtsuki, T., Hori, M., et al. (1998). Deficiency of intercellular adhesion molecule 1 attenuates microcirculatory disturbance and infarction size in focal cerebral ischemia. Journal of Cerebral Blood Flow and Metabolism, 18, 1336-1345.
92. Khan, M., Jatana, M., Elango, C., Singh, P. A., Singh, A. K., & Singh, I. (2006). Cerebrovascular protection by various nitric oxide donors in rats after experimental stroke. Nitric Oxide, 15, 114-124.
93. Vemuganti, R., Dempsey, R. J., & Bowen, K. K. (2004). Inhibition of intercellular adhesion molecule-1 protein expression by antisense oligonucleotides is neuroprotective after transient middle cerebral artery occlusion in rat. Stroke, 35, 179-184.
94. Shyu, K. G., Chang, H., & Lin, C. C. (1997). Serum levels of intercellular adhesion molecule-1 and E-selectin in patients with acute ischaemic stroke. Journal of Neurology, 244, 90-93.
95. Lindsberg, P. J., Carpen, O., Paetau, A., Karjalainen-Lindsberg, M. L., & Kaste, M. (1996). Endothelial ICAM-1 expression associated with inflammatory cell response in human ischemic stroke. Circulation, 94, 939-945.
96. Enlimomab, A. S. T. (2001). Use of anti-ICAM-1 therapy in ischemic stroke: results of the Enlimomab Acute Stroke Trial. Neurology, 57, 1428-1434.
97. Vuorte, J., Lindsberg, P. J., Kaste, M., Meri, S., Jansson, S. E., Rothlein, R., et al. (1999). Anti-ICAM-1 monoclonal antibody R6.5 (Enlimomab) promotes activation of neutrophils in whole blood. Journal of Immunology, 162, 2353-2357.
98. Zhang, L. H., & Wei, E. Q. (2003). Neuroprotective effect of ONO-1078, a leukotriene receptor antagonist, on transient global cerebral ischemia in rats. Acta Pharmacologica Sinica, 24, 1241-1247.
99. Justicia, C., Martin, A., Rojas, S., Gironella, M., Cervera, A., Panes, J., et al. (2006). Anti-VCAM-1 antibodies did not protect against ischemic damage either in rats or in mice. Journal of Cerebral Blood Flow and Metabolism, 26, 421-432.
100. Bajetto, A., Bonavia, R., Barbero, S., Florio, T., & Schettini, G. (2001). Chemokines and their receptors in the central nervous system. Frontiers in Neuroendocrinology, 22, 147-184.
101. Chen, Y., Hallenbeck, J. M., Ruetzler, C., Bol, D., Thomas, K., Berman, N. E., et al. (2003). Overexpression of monocyte chemoattractant protein 1 in the brain exacerbates ischemic brain injury and is associated with recruitment of inflammatory cells. Journal of Cerebral Blood Flow and Metabolism, 23, 748-755.
102. Lambertsen, K. L., Biber, K., & Finsen, B. (2012). Inflammatory cytokines in experimental and human stroke. Journal of Cerebral Blood Flow and Metabolism, 32, 1677-1698.
103. Wang, L., Li, Y., Chen, X., Chen, J., Gautam, S. C., Xu, Y., et al. (2002). MCP-1, MIP-1, IL-8 and ischemic cerebral tissue enhance human bone marrow stromal cell migration in interface culture. Hematology, 7, 113-117.
104. Wang, L., Li, Y., Chen, J., Gautam, S. C., Zhang, Z., Lu, M., et al. (2002). Ischemic cerebral tissue and MCP-1 enhance rat bone marrow stromal cell migration in interface culture. Experimental Hematology, 30, 831-836.
105. Lee, S. R., Kim, H. Y., Rogowska, J., Zhao, B. Q., Bhide, P., Parent, J. M., et al. (2006). Involvement of matrix metalloproteinase in neuroblast cell migration from the subventricular zone after stroke. Journal of Neuroscience, 26, 3491-3495.
106. Zhao, B. Q., Wang, S., Kim, H. Y., Storrie, H., Rosen, B. R., Mooney, D. J., et al. (2006). Role of matrix metalloproteinases in delayed cortical responses after stroke. Nature Medicine, 12, 441-445.
107. Rosenberg, G. A., Navratil, M., Barone, F., & Feuerstein, G. (1996). Proteolytic cascade enzymes increase in focal cerebral ischemia in rat. Journal of Cerebral Blood Flow and Metabolism, 16, 360-366.
108. Clark, A. W., Krekoski, C. A., Bou, S. S., Chapman, K. R., & Edwards, D. R. (1997). Increased gelatinase A (MMP-2) and gelatinase B (MMP-9) activities in human brain after focal ischemia. Neuroscience Letters, 238, 53-56.
109. Castellanos, M., Leira, R., Serena, J., Pumar, J. M., Lizasoain, I., & Castillo, J. (2003). Plasma metalloproteinase-9 concentration predicts hemorrhagic transformation in acute ischemic stroke. Stroke, 34, 40-46.
110. Montaner, J., Alvarez-Sabin, J., Molina, C., Angles, A., Abilleira, S., & Arenillas, J. (2001). Matrix metalloproteinase expression after human cardioembolic stroke: temporal profile and relation to neurological impairment. Stroke, 32, 1759-1766.
111. Asahi, M., Wang, X., Mori, T., Sumii, T., Jung, J. C., Moskowitz, M. A., et al. (2001). Effects of matrix metalloproteinase-9 gene knock-out on the proteolysis of blood-brain barrier and white matter components after cerebral ischemia. Journal of Neuroscience, 21, 7724-32.
112. Tarkowski, E., Rosengren, L., Blomstrand, C., Wikkelso, C., Jensen, C., Ekholm, S., et al. (1997). Intrathecal release of pro- and anti-inflammatory cytokines during stroke. Clinical and Experimental Immunology, 110, 492-499.
113. Pelidou, S. H., Kostulas, N., Matusevicius, D., Kivisakk, P., Kostulas, V., & Link, H. (1999). High levels of IL-10 secreting cells are present in blood in cerebrovascular diseases. European Journal of Neurology, 6, 437-442.
114. Strle, K., Zhou, J. H., Shen, W. H., Broussard, S. R., Johnson, R. W., Freund, G. G., et al. (2001). Interleukin-10 in the brain. Critical Reviews in Immunology, 21, 427-449.
115. Grilli, M., Barbieri, I., Basudev, H., Brusa, R., Casati, C., Lozza, G., et al. (2000). Interleukin-10 modulates neuronal threshold of vulnerability to ischaemic damage. European Journal of Neuroscience, 12, 2265-2272.
116. Kim, J. S., Yoon, S. S., Kim, Y. H., & Ryu, J. S. (1996). Serial measurement of interleukin-6, transforming growth factor-beta, and S 100 protein in patients with acute stroke. Stroke, 27, 1553-1557.
117. van Exel, E., Gussekloo, J., de Craen, A. J., Bootsma-van, D. W. A., Frolich, M., & Westendorp, R. G. (2002). Inflammation and stroke: the Leiden 85-Plus Study. Stroke, 33, 1135-1138.
118. Buckwalter, M., & Wyss-Coray, T. (2004). Modelling neuroinflammatory phenotypes in vivo. Journal of Neuroinflammation, 1, 10.
119. Klempt, N. D., Sirimanne, E., Gunn, A. J., Klempt, M., Singh, K., & Williams, C. (1992). Hypoxia-ischemia induces transforming growth factor beta 1 mRNA in the infant rat brain. Molecular Brain Research, 13, 93-101.
120. Wienner, C., Gehrmann, J., Lindholm, D., Topper, R., Kreutzberg, G. W., & Hossmann, K. A. (1993). Expression of transforming growth factor-beta1 and interleukin-1 beta mRNA in rat brain following transient fore-brain ischemia. Acta Neuropathologica, 86, 439-46.
121. Johnston, R. E., Dillon-Carter, O., Freed, W. J., & Borlongan, C. V. (2001). Trophic factor secreting kidney cell lines: in vitro characterization and functional effects following transplantation in ischemic rats. Brain Research, 900, 268-276.
122. Sun, H., Gong, S., Carmody, R. J., Hilliard, A., Li, L., Sun, J., et al. (2008). TIPE2, a negative regulator of innate and adaptive immunity that maintains immune homeostasis. Cell, 133, 415-426.
123. Zhang, X., Wang, J., Fan, C., Li, H., Sun, H., Gong, S., et al. (2009). Crystal structure of TIPE2 provides insights into immune homeostasis. Nature Structural and Molecular Biology, 16, 89-90.
124. Kooijman, R. (2006). Regulation of apoptosis by insulin-like growth factor (IGF)-I. Cytokine & Growth Factor Reviews, 17, 305-323.
125. Liu, X. F., Fawcett, J. R., Hanson, L. R., & Frey, W. H. (2004). The window of opportunity for treatment of focal cerebral ischemic damage with noninvasive intranasal insulin-like growth factor-I in rats. Journal of Stroke and Cerebrovascular Diseases, 13, 16-23.
126. Liu, X. F., Fawcett, J. R., Thorne, R. G., DeFor, T. A., & Frey, W. H. (2001). Intranasal administration of insulin-like growth factor-I bypasses the blood-brain barrier and protects against focal cerebral ischemic damage. Journal of Neurological Sciences, 187, 91-97.
127. De, S. A., Brouns, R., Uyttenboogaart, M., De, R. S., Moens, M., Wilczak, N., et al. (2011). Insulin-like growth factor I serum levels influence ischemic stroke outcome. Stroke, 42, 2180-2185.
128. Bsibsi, M., Persoon-Deen, C., Verwer, R. W., Meeuwsen, S., Ravid, R., & Van, N. J. M. (2006). Toll-like receptor 3 on adult human astrocytes triggers production of neuroprotective mediators. Glia, 53, 688-695.
129. Bsibsi, M., Ravid, R., Gveric, D., & Van Noort, J. M. (2002). Broad expression of Toll-like receptors in the human central nervous system. Journal of Neuropathology and Experimental Neurology, 61, 1013-1021.
130. Singh, A. K., & Jiang, Y. (2004). How does peripheral lipopolysaccharide induce gene expression in the brain of rats? Toxicology, 201, 197-207.
131. Jack, C. S., Arbour, N., Manusow, J., Montgrain, V., Blain, M., McCrea, E., et al. (2005). TLR signaling tailors innate immune responses in human microglia and astrocytes. Journal of Immunology, 175, 4320-4330.
132. Marsh, B. J., Williams-Karnesky, R. L., & Stenzel-Poore, M. P. (2009). Toll-like receptor signaling in endogenous neuroprotection and stroke. Neuroscience, 158, 1007-1020.
133. Sakata, Y., Dong, J. W., Vallejo, J. G., Huang, C. H., Baker, J. S., Tracey, K. J., et al. (2007). Toll-like receptor 2 modulates left ventricular function following ischemia-reperfusion injury. American Journal of Physiology - Heart and Circulatory Physiology, 292, H503-H509.
134. Shigeoka, A. A., Holscher, T. D., King, A. J., Hall, F. W., Kiosses, W. B., Tobias, P. S., et al. (2007). TLR2 is constitutively expressed within the kidney and participates in ischemic renal injury through both MyD88-dependent and -independent pathways. Journal of Immunology, 178, 6252-6258.
135. Cao, C. X., Yang, Q. W., Lv, F. L., Cui, J., Fu, H. B., & Wang, J. Z. (2007). Reduced cerebral ischemia-reperfusion injury in Toll-like receptor 4 deficient mice. Biochemical and Biophysical Research Communications, 353, 509-514.
136. Lehnardt, S., Schott, E., Trimbuch, T., Laubisch, D., Krueger, C., Wulczyn, G., et al. (2008). A vicious cycle involving release of heat shock protein 60 from injured cells and activation of toll-like receptor 4 mediates neurodegeneration in the CNS. Journal of Neuroscience, 28, 2320-2331.
137. Ziegler, G., Harhausen, D., Schepers, C., Hoffmann, O., Rohr, C., Prinz, V., et al. (2007). TLR2 has a detrimental role in mouse transient focal cerebral ischemia. Biochemical and Biophysical Research Communications, 359, 574-579.
138. Caso, J. R., Pradillo, J. M., Hurtado, O., Lorenzo, P., Moro, M. A., & Lizasoain, I. (2007). Toll-like receptor 4 is involved in brain damage and inflammation after experimental stroke. Circulation, 115, 1599-1608.
139. Hua, F., Ma, J., Ha, T., Xia, Y., Kelley, J., Williams, D. L., et al. (2007). Activation of Toll-like receptor 4 signaling contributes to hippocampal neuronal death following global cerebral ischemia/reperfusion. Journal of Neuroimmunology, 190, 101-111.
140. Kinouchi, H., Sharp, F. R., Hill, M. P., Koistinaho, J., Sagar, S. M., & Chan, P. H. (1993). Induction of 70-kDa heat shock protein and hsp70 mRNA following transient focal cerebral ischemia in the rat. Journal of Cerebral Blood Flow and Metabolism, 13, 105-115.
141. Faraco, G., Fossati, S., Bianchi, M. E., Patrone, M., Pedrazzi, M., Sparatore, B., et al. (2007). High mobility group box 1 protein is released by neural cells upon different stresses and worsens ischemic neurodegeneration in vitro and in vivo. Journal of Neurochemistry, 103, 590-603.
142. Schneider, A., Martin-Villalba, A., Weih, F., Vogel, J., Wirth, T., & Schwaninger, M. (1999). NF-kappaB is activated and promotes cell death in focal cerebral ischemia. Nature Medicine, 5, 554-559.
143. Liu, H., Xin, L., Chan, B. P. L., Teoh, R., Tang, B. L., & Tan, Y. H. (2002). Interferon beta administration confers a beneficial outcome in a rabbit model of thromboembolic cerebral ischemia. Neuroscience Letters, 327, 146-148.
144. Veldhuis, W., Derksen, J., Floris, S., Vander, M. P., de Vries, H., Schepers, J., et al. (2003). Interferon-beta blocks infiltration of inflammatory cells and reduces infarct volume after ischemic stroke in the rat. Journal of Cerebral Blood Flow and Metabolism, 23, 1029-1039.
145. Bogoyevitch, M. A., Gillespie-Brown, J., Ketterman, A. J., Fuller, S. J., Ben-Levy, R., Ashworth, A., et al. (1996). Stimulation of the stress-activated mitogen-activated protein kinase subfamilies in perfused heart. p38/RK mitogen-activated protein kinases and c-Jun N-terminal kinases are activated by ischemia/reperfusion. Circulation Research, 79, 162-173.
146. Ferrell, J. E. (1996). Tripping the switch fantastic: how a protein kinase cascade can convert graded inputs into switch-like outputs. Trends in Biochemical Sciences, 21, 460-466.
147. Davis, R. J. (1993). The mitogen-activated protein kinase signal transduction pathway. Journal of Biological Chemistry, 268, 14553-14556.
148. Nithianandarajah-Jones, G. N., Wilm, B., Goldring, C. E., Müller, J., & Cross, M. J. (2012). ERK5: structure, regulation and function. Cellular Signalling, 24, 2187-2196.
149. Lewis, T. S., Shapiro, P. S., & Ahn, N. G. (1998). Signal transduction through MAP kinase cascades. Advances in Cancer Research, 74, 49-139.
150. Sutton, L. N., Clark, B. J., Norwood, C. R., Woodford, E. J., & Welsh, F. A. (1991). Global cerebral ischemia in piglets under conditions of mild and deep hypothermia. Stroke, 22, 1567-1573.
151. Kamme, F., Camp, K., & Wieloch, T. (1995). Biphasic expression of the fos and jun families of transcription factors following transient forebrain ischaemia in the rat. Effect of hypothermia. European Journal of Neuroscience, 7, 2007-2016.
152. Wang, Z. Q., Wu, D. C., Huang, F. P., & Yang, G. Y. (2004). Inhibition of MEK/ERK 1/2 pathway reduces pro-inflammatory cytokine interleukin-1 expression in focal cerebral ischemia. Brain Research, 996, 55-66.
153. Barnes, P. J. (2010). Mechanisms and resistance in glucocorticoid control of inflammation. Journal of Steroid Biochemistry and Molecular Biology, 120, 6-85.
154. Woo, C. H., Massett, M. P., Shishido, T., Itoh, S., Ding, B., McClain, C., et al. (2006). ERK5 activation inhibits inflammatory responses via peroxisome proliferator-activated receptor delta (PPARdelta) stimulation. Journal of Biological Chemistry, 281, 32164-32174.
155. Xia, Z., Dickens, M., Raingeaud, J., Davis, R. J., & Greenberg, M. E. (1995). Opposing effects of ERK and JNK-p38 MAP kinases on apoptosis. Science, 270, 1326-1331.
156. Kawasaki, H., Morooka, T., Shimohama, S., Kimura, J., Hirano, T., Gotoh, Y., et al. (1997). Activation and involvement of p38 mitogen-activated protein kinase in glutamate-induced apoptosis in rat cerebellar granule cells. Journal of Biological Chemistry, 272, 18518-18521.
157. Guan, Q. H., Pei, D. S., Zong, Y. Y., Xu, T. L., & Zhang, G. Y. (2006). Neuroprotection against ischemic brain injury by a small peptide inhibitor of c-Jun N-terminal kinase (JNK) via nuclear and non-nuclear pathways. Neuroscience, 139, 609-627.
158. Sawe, N., Steinberg, G., & Zhao, H. (2008). Dual roles of the MAPK/ERK1/2 cell signaling pathway after stroke. Journal of Neuroscience Research, 86, 1659-1669.
159. Benakis, C., Bonny, C., & Hirt, L. (2010). JNK inhibition and inflammation after cerebral ischemia. Brain, Behavior, and Immunity, 24, 800-811.
160. Kaminska, B. (2005). MAPK signalling pathways as molecular targets for anti-inflammatory therapy - from molecular mechanisms to therapeutic benefits. Biochimica et Biophysica Acta, 1754, 253-262.
161. Wang, L. W., Tu, Y. F., Huang, C. C., & Ho, C. J. (2012). JNK signaling is the shared pathway linking neuroinflammation, blood-brain barrier disruption, and oligodendroglial apoptosis in the white matter injury of the immature brain. Journal of Neuroinflammation, 17, 175.
162. Barone, F. C., Irving, E. A., & Ray, A. M. (2001). Inhibition of p38 mitogen-activated protein kinase provides neuroprotection in cerebral focal ischemia. Medicinal Research Reviews, 21, 129-145.
163. Wang, H., Xu, L., Venkatachalam, S., Trzaskos, J. M., Friedman, S. M., Feuerstein, G. Z., et al. (2001). Differential regulation of IL-1beta and TNF-alpha RNA expression by MEK1 inhibitor after focal cerebral ischemia in mice. Biochemical and Biophysical Research Communications, 286, 869-874.
164. Maddahi, A., & Edvinsson, L. (2008). Enhanced expressions of microvascular smooth muscle receptors after focal cerebral ischemia occur via the MAPK MEK/ERK pathway. BMC Neuroscience, 9, 85.
165. Alessandrini, A., Namura, S., Moskowitz, M. A., & Bonventre, J. V. (1999). MEK1 protein kinase inhibition protects against damage resulting from focal cerebral ischemia. Proceedings of the National Academy of Sciences of the United States of America, 96, 12866-12869.
166. Wang, X., Wang, H., Xu, L., Rozanski, D. J., Sugawara, T., Chan, P. H., et al. (2003). Significant neuroprotection against ischemic brain injury by inhibition of the MEK1 protein kinase in mice: exploration of potential mechanism associated with apoptosis. Journal of Pharmacology and Experimental Therapeutics, 304, 172-178.
167. Roux, P. P., & Blenis, J. (2004). ERK and p38 MAPK-activated protein kinases: a family of protein kinases with diverse biological functions. Microbiology and Molecular Biology Reviews, 68, 320-344.
168. Han, B. H., & Holtzman, D. M. (2000). BDNF protects the neonatal brain from hypoxic-ischemic injury in vivo via the ERK pathway. Journal of Neuroscience, 20, 5775-5781.
169. Wang, R. M., Zhang, Q. G., Li, J., Yang, L. C., Yang, F., & Brann, D. W. (2009). The ERK5-MEF2C transcription factor pathway contributes to anti-apoptotic effect of cerebral ischemia preconditioning in the hippocampal CA1 region of rats. Brain Research, 1255, 32-41.
170. Ridder, D. A., & Schwaninger, M. (2009). NF-kappaB signaling in cerebral ischemia. Neuroscience, 158, 995-1006.
171. Napetschnig, J., & Wu, H. (2013). Molecular basis of NF-κB signaling. Annual Review of Biophysics, 42, 443-68.
172. Khan, M., Sekhon, B., Giri, S., Jatana, M., Gilg, A. G., Ayasolla, K., et al. (2005). S-Nitrosoglutathione reduces inflammation and protects brain against focal cerebral ischemia in a rat model of experimental stroke. Journal of Cerebral Blood Flow and Metabolism, 25, 177-192.
173. Hill, W. D., Hess, D. C., Carroll, J. E., Wakade, C. G., Howard, E. F., Chen, Q., et al. (2001). The NF-kappaB inhibitor diethyldithiocarbamate (DDTC) increases brain cell death in a transient middle cerebral artery occlusion model of ischemia. Brain Research Bulletin, 55, 375-86.
174. Smith, C. J., Emsley, H. C., Vail, A., Georgiou, R. F., Rothwell, N. J., Tyrrell, P. J., et al. (2006). Variability of the systemic acute phase response after ischemic stroke. Journal of Neurological Sciences, 251, 77-81.
175. Palasik, W., Fiszer, U., Lechowicz, W., Czartoryska, B., Krzesiewicz, M., & Lugowska, A. (2005). Assessment of relations between clinical outcome of ischemic stroke and activity of inflammatory processes in the acute phase based on examination of selected parameters. European Neurology, 53, 188-193.
176. McColl, B. W., Rothwell, N. J., & Allan, S. M. (2008). Systemic inflammation alters the kinetics of cerebrovascular tight junction disruption after experimental stroke in mice. Journal of Neuroscience, 28, 9451-9462.
177. Dandona, P., Aljada, A., & Bandyopadhyay, A. (2004). Inflammation: the link between insulin resistance, obesity and diabetes. Trends in Immunology, 25, 4-7.
178. Hansson, G. K., & Libby, P. (2006). The immune response in atherosclerosis: a double-edged sword. Nature Reviews Immunology, 6, 508-519.
179. McGill, J. K., Gallagher, L., Carswell, H. V., Irving, E. A., Dominiczak, A. F., & Macrae, I. M. (2005). Impaired functional recovery after stroke in the stroke-prone spontaneously hypertensive rat. Stroke, 36, 135-141.
180. Tureyen, K., Kapadia, R., Bowen, K. K., Satriotomo, I., Liang, J., Feinstein, D. L., et al. (2007). Peroxisome proliferator-activated receptor-gamma agonists induce neuroprotection following transient focal ischemia in normotensive, normoglycemic as well as hypertensive and type-2 diabetic rodents. Journal of Neurochemistry, 101, 41-56.
181. Warlow, C., Sudlow, C., Dennis, M., Wardlaw, J., & Sandercock, P. (2003). Stroke. Lancet, 362, 1211-1224.
182. Krakauer, J. W. (2007). The complex dynamics of stroke onset and progression. Current Opinion in Neurology, 20, 47-50.
183. Amantea, D., Nappi, G., Bernardi, G., Bagetta, G., & Corasaniti, M. T. (2009). Post-ischemic brain damage: pathophysiology and role of inflammatory mediators. FEBS Journal, 276, 13-26.
184. Kriz, J. (2006). Inflammation in ischemic brain injury: timing is important. Critical Reviews in Neurobiology, 18, 145-157.
185. Ruehl, M. L., Orozco, J. A., Stoker, M. B., McDonagh, P. F., Coull, B. M., & Ritter, L. S. (2002). Protective effects of inhibiting both blood and vascular selectins after stroke and reperfusion. Neurological Research, 24, 226-232.
186. Zhang, R. L., Chopp, M., Jiang, N., Tang, W. X., Prostak, J., Manning, A. M., et al. (1995). Anti-intercellular adhesion molecule-1 antibody reduces ischemic cell damage after transient but not permanent middle cerebral artery occlusion in the Wistar rat. Stroke, 26, 1438-1442.
187. Chopp, M., Zhang, R. L., Chen, H., Li, Y., Jiang, N., & Rusche, J. R. (1994). Postischemic administration of an anti-Mac-1 antibody reduces ischemic cell damage after transient middle cerebral artery occlusion in rats. Stroke, 25, 869-875.
188. Ma, M., Ma, Y., Yi, X., Guo, R., Zhu, W., Fan, X., et al. (2008). Intranasal delivery of transforming growth factor-beta1 in mice after stroke reduces infarct volume and increases neurogenesis in the subventricular zone. BMC Neuroscience, 10, 117.
189. Veldhoen, M., Hocking, R. J., Atkins, C. J., Locksley, R. M., & Stockinger, B. (2006). TGFbeta in the context of an inflammatory cytokine milieu supports de novo differentiation of IL-17-producing T cells. Immunity, 24, 179-189.
190. Taylor, A., Verhagen, J., Blaser, K., Akdis, M., & Akdis, C. A. (2006). Mechanisms of immune suppression by interleukin-10 and transforming growth factor-beta: the role of T regulatory cells. Immunology, 117, 433-442.
191. Emsley, H. C., Smith, C. J., Georgiou, R. F., Vail, A., Hopkins, S. J., Rothwell, N. J., et al. (2005). Acute stroke investigators: a randomised phase II study of interleukin-1 receptor antagonist in acute stroke patients. Journal of Neurology, Neurosurgery, and Psychiatry, 76, 1366-1372.
192. Krams, M., Lees, K. R., Hacke, W., Grieve, A. P., Orgogozo, J. M., & Ford, G. A. (2003). ASTIN Study Investigators. Acute Stroke Therapy by Inhibition of Neutrophils (ASTIN): an adaptive dose-response study of UK-279,276 in acute ischemic stroke. Stroke, 34, 2543-2548.
193. Becker, K. J. (2002). Anti-leukocyte antibodies: LeukArrest (Hu23F2G) and Enlimomab (R6.5) in acute stroke. Current Medical Research and Opinion, 18, s18-22.
194. Danton, G. H., & Dietrich, W. D. (2003). Inflammatory mechanisms after ischemia and stroke. Neuropathology and Experimental Neurology, 62, 127-136.
195. Minnerup, J., Sutherland, B. A., Buchan, A. M., & Kleinschnitz, C. (2012). Neuroprotection for stroke: current status and future perspectives. International Journal of Molecular Sciences, 13, 11753-11772.
196. Mergenthaler, P., & Meisel, A. (2012). Do stroke models model stroke? Disease Models & Mechanisms, 5, 718-725.
197. Zaremba, J., & Losy, J. (2001). Early TNF-α levels correlate with ischemic stroke severity. Acta Neurologica Scandinavica, 104, 288-295.